Russia, Turkey may discuss purchase of S-400 systems at March talksMilitary & Defense February 22, 19:18
European human rights watchdog welcomes court’s ruling on Russian opposition activistWorld February 22, 18:42
Maslenitsa festival: a week of pancakes and joySociety & Culture February 22, 17:49
Kremlin aide praises late UN envoy as ‘generation’s best and brightest’ diplomatRussian Politics & Diplomacy February 22, 17:28
Russian only Polar Circle city vows to preserve Arctic environmentBusiness & Economy February 22, 17:20
Russian presidential aide says Astana platform helpful for settling Syrian crisisRussian Politics & Diplomacy February 22, 16:55
UN high commissioner urges Europe’s ‘cooperative approach’ to migration situationWorld February 22, 16:51
Russia's defense chief to mobilize new cyber armyMilitary & Defense February 22, 16:49
Presidential aide says all Kremlin’s contacts with Trump administration already reportedRussian Politics & Diplomacy February 22, 16:36
MOSCOW, April 14 (Itar-Tass) —— The Russian Skolkovo innovation centre’s resident company is developing innovative medicines against AIDS.
“These medicines use an absolutely new mechanism of action. Molecules affect structural protein that is critical for the HIV virus,” Quantum Pharmaceuticals Deputy Director Maxim Kholin said in an exclusive interview with Itar-Tass.
“The mechanism of action has its peculiarities and they allow us to expect our medicines to be less toxic for the human organism than many others now available. This is very important because the development of medicines against HIV is facing two problems: the virus is highly variable and medicines are toxic,” Kholin noted.
“We are continuing research and getting good results,” he added.
“Skolkovo has supported our project and helped us move forward considerably. It’s important to say that the substances have been developed using our own molecular modelling technology, one of the leading technologies in the world. We also actively use this technological platform for developing other antiviral medicines, new cancer medications and antibiotics. We work both on our own and in partnership with leading international research centres,” Kholin said.